See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Natural Disasters
Social Media
Artificial Intelligence
Baseball
Stock Markets
Tennis
Golf
Cricket
Tariffs
Infrastructure
European Union
Published • loading... • Updated

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates

Summary by MyChesCo
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, alongside significant corporate updates. The biotechnology company reaffirmed its commitment to advancing its pipeline for chronic hepatitis B (cHBV) while implementing multiple strategic measures to improve financial and operational efficiency. Arbutus ended 2024 with $122.6 million in combined cash, cas…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
MyChesCoMyChesCo

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, alongside significant corporate updates. The biotechnology company reaffirmed its commitment to advancing its pipeline for chronic hepatitis B (cHBV) while implementing multiple strategic measures to improve financial and operational efficiency. Arbutus ended 2024 with $122.6 million in combined cash, cas…

Read Full Article
tickerreport.comtickerreport.com

Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. The company had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

tickerreport.com broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Chester County, Pennsylvania

Chester County, Pennsylvania

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal